Highlights • Some races, ethnicities, geographies, genders, ages, abilities, and economic classes are underrepresented in cancer trials. • There is strong scientific and ethical rationale for inclusiveness, equity, and diversity in cancer trial populations. • Stakeholders including regulators, sponsors, CROs, patient groups, and oncology journals are advocating for such diversity. • Cancer trials should answer scientific questions of relevance to the diverse participating subgroups.
All Keywords
【저자키워드】 clinical trials, Diversity, equity, Inclusion, regulators,
【저자키워드】 clinical trials, Diversity, equity, Inclusion, regulators,